Bing

SEARCH HISTORY

Under the terms of the agreement, which was approved by the Boards of Directors of both companies, a subsidiary of Avago will commence a tender offer for all of the outstanding shares of PLX common stock for $6.50 per share in cash. Avago expects to …
Briefing Live Market Analysis · 6/23/2014
Equities researchers at Jefferies Group began coverage on shares of Protalix BioTherapeutics (NYSE:PLX) in a research report issued on Thursday. The firm set a “buy” rating and a $2.60 price target on the stock. Jefferies Group’s target price ...
Ticker Report · 4/23/2015
As of the expiration of the offer at 12:00 midnight New York City time on August 11, 2014, a total of 40,993,851 shares had been validly tendered and not withdrawn, representing approximately 80.3% of the outstanding shares of common stock of PLX on a ...
Market Watch · 8/12/2014
More from Bing News
Based on IDT’s closing stock price on April 27, 2012, the transaction is valued at approximately $7.00 per PLX share and results in a total transaction value of approximately $330 million. “The proposed acquisition of PLX Technology represents an ...
Business Wire · 4/30/2012
Protalix BioTherapeutics Inc. (NYSEMKT:PLX) share price has entered into oversold territory with an RSI value of 22.9. The Zacks Consensus Estimate on Protalix BioTherapeutics Inc.’s earnings for the full year period has profit of 0.07 cents over the ...
efinancehub.com · 12/2/2013
Today, Cheniere Energy Partners L.P (CQP) is down on high volume, trading at a volume of 723,048, or 4.3 times its average daily volume. The stock is down 14.8% to $19.50. The share price has been falling in the last month, down $6.10 (-23.8%) from $25.
Fox Business · 6/4/2012
PLX Technology Inc. (NASDAQ:PLXT ... Over the subsequent weeks, the stock moved from around $3.00 to more than $3.70 per share. According to a recent regulatory filing: Mr. Michael believes that management should seek a buyer for the issuer to take ...
Seeking Alpha · ByJustin Kuepper · 2/19/2012
at the Tel Aviv Stock Exchange's conference center. Pluristem's executive management team will speak about the strategic importance of its latest regulatory progress including: European Medicines Agency's selection of Pluristem's PLX cell program in ...
GlobeNewswire · 5/19/2015
One such stock is Israel-based micro-cap by the name of Protalix BioTherapeutics Inc. (PLX), which gained 11% during trading yesterday and is up another 6% in extended trading as the Street continues to discover that the company could reap immense …
bidnessetc.com · 10/14/2014
HAIFA, Israel, May 18, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced a significant advancement to its clinical development plan: the …
Stockhouse · 5/18/2015